Lilly's Weight-Loss Pill Approved, Sparking Competition with Novo Nordisk
Eli Lilly's daily weight-loss pill received FDA approval, setting the stage for a competitive battle with Novo Nordisk's Wegovy in the $70 billion GLP-1 market.
- Publisher
- The Wall Street Journal
- Published
- Length
- 30 pages
- File
- 7.6 MB PDF
Download the full 30-page PDF
Free · 7.6 MB · Instant access after email
Eli Lilly's once-daily weight-loss pill has gained FDA approval, marking a significant milestone in the GLP-1 drug market. Key points include:
- The approval positions Lilly to compete directly with Novo Nordisk's Wegovy.
- The GLP-1 market is projected to exceed $70 billion.
- Lilly aims to leverage its existing dominance in diabetes treatments to capture market share.
- Analysts predict a fierce competition between Lilly and Novo Nordisk for leadership in this lucrative sector.
Ready to read the full report?
Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.
More whitepapers like this
🔒 Patient Mastering as Enterprise Infrastructure
Effective patient mastering is crucial for healthcare organizations to ensure accurate patient journeys and reliable analytics, impacting strategic decisions and financial outcomes.
🔒 Cigna Medical Coverage Policy: Acupuncture
Cigna's updated policy outlines conditions for acupuncture coverage, including migraine and musculoskeletal pain, effective April 2026.
🔒 Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only)
This policy outlines medically necessary radiation therapy protocols for conditions like breast cancer and lung cancer, effective April 1, 2026.